Translating Science to Improve Health: Hope for Patients With Kidney Disease at What Cost?
Authors: Delphine S. Tuot, Neil R. Powe
Journal: Annals of Internal Medicine (2013)

Editorials17 September 2013Translating Science to Improve Health: Hope for Patients With Kidney Disease at What Cost?Delphine S. Tuot, MDCM, MAS and Neil R. Powe, MD, MPH, MBADelphine S. Tuot, MDCM, MASFrom San Francisco General Hospital and University of California, San Francisco, San Francisco, California.Search for more papers by this author and Neil R. Powe, MD, MPH, MBAFrom San Francisco General Hospital and University of California, San Francisco, San Francisco, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-159-6-201309170-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail High health care costs in the United States not only threaten the health care delivery system but also overall U.S. economic well-being. Efforts to control costs while maintaining or improving the quality of care are important for patients, clinicians, and policymakers. As such, the medical community has recently focused on high-value interventions (those that provide a substantial net health improvement relative to their costs) (1). Although the U.S. Food and Drug Administration considers only safety and effectiveness in its decisions to approve new drugs and biologics and policy prohibits the Medicare program from considering cost-effectiveness in its coverage decisions for ...References1. Owens DK, Qaseem A, Chou R, and Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154:174-80 LinkGoogle Scholar2. Erickson KF, Chertow GM, and Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med. 2013;159:382-9. LinkGoogle Scholar3. Torres VE, Harris PC, and Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287-301. [PMID: 17434405] CrossrefMedlineGoogle Scholar4. United States Renal Data System. United States Renal Data System 2012 Annual Data Report. Volume One: Atlas of Chronic Kidney Disease in the United States and Volume Two: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Google Scholar5. Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens. 2012;21:189-94. [PMID: 22274800] CrossrefMedlineGoogle Scholar6. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407-18. [PMID: 23121377] CrossrefMedlineGoogle Scholar7. Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva, Switzerland World Health Organization 2003. Google Scholar8. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59:504-12. [PMID: 22284441] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Delphine S. Tuot, MDCM, MAS; Neil R. Powe, MD, MPH, MBAAffiliations: From San Francisco General Hospital and University of California, San Francisco, San Francisco, California.Financial Support: Dr. Tuot is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK094850).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-1886.Corresponding Author: Delphine S. Tuot, MDCM, MAS, Division of Nephrology, San Francisco General Hospital, 1001 Potrero Avenue, Building 100, Room 342, San Francisco, CA 94110; e-mail, [email protected].Current Author Addresses: Dr. Tuot: Division of Nephrology, San Francisco General Hospital, 1001 Potrero Avenue, Building 100, Room 342, San Francisco, CA 94110.Dr. Powe: Chief of Medicine, San Francisco General Hospital, 1001 Potrero Avenue, Room 5F40, San Francisco, CA 94110. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Metrics 17 September 2013Volume 159, Issue 6Page: 430-431KeywordsAttentionDrug administrationDrug deliveryDrug policyDrug safetyDrugsFoodHealth careHealth care policyHealth care qualityHypertensionHyponatremiaKidneysLife expectancyMedicarePatient advocacyPolycystic kidney diseasePrevention, policy, and public healthRenal failureSafety ePublished: 17 September 2013 Issue Published: 17 September 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...